Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma
Phase 1
Completed
- Conditions
- Melanoma
- Interventions
- Biological: tvs-CTL Vaccine
- First Posted Date
- 2015-06-26
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Gary Doolittle
- Target Recruit Count
- 7
- Registration Number
- NCT02482532
- Locations
- 🇺🇸
KU Cancer Center, Fairway, Kansas, United States
© Copyright 2025. All Rights Reserved by MedPath